Related coverage linked through entity extraction aliases.
Feb 23, 2026
Benitec Biopharma will present interim clinical study results for BB-301 gene therapy in oculopharyngeal muscular dystrophy patients at the Muscular Dystrophy Association Conference on March 9, 2026, including 12-month and 24-month follow-up data.
Feb 17, 2026
BioNxt Solutions Inc. receives European Patent No. 4539857 for its proprietary sublingual cladribine oral thin film drug delivery technology, providing protection across up to 39 European Patent Convention states through at least June 14, 2043.
Feb 14, 2026
New research and precision radiation techniques aim to minimize debilitating side effects of head and neck cancer treatment, including oral mucositis, while maintaining tumor control and improving patient quality of life.
